Wolfe Research assumed coverage on shares of Grail (NASDAQ:GRAL - Free Report) in a report issued on Friday, MarketBeat.com reports. The brokerage issued a peer perform rating on the stock.
Separately, Guggenheim started coverage on shares of Grail in a report on Thursday, October 17th. They issued a "neutral" rating on the stock.
Read Our Latest Analysis on Grail
Grail Stock Performance
NASDAQ:GRAL traded down $1.01 during midday trading on Friday, hitting $14.80. 831,894 shares of the company traded hands, compared to its average volume of 1,094,071. Grail has a 12-month low of $12.33 and a 12-month high of $23.36. The firm has a fifty day moving average price of $13.78.
Grail (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($5.30) earnings per share for the quarter. The business had revenue of $31.97 million during the quarter.
Insider Buying and Selling
In related news, major shareholder Chun R. Ding bought 16,200 shares of the stock in a transaction dated Wednesday, October 9th. The shares were purchased at an average price of $12.92 per share, for a total transaction of $209,304.00. Following the completion of the purchase, the insider now directly owns 3,644,855 shares of the company's stock, valued at $47,091,526.60. This represents a 0.45 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert P. Ragusa sold 123,454 shares of Grail stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total value of $1,730,825.08. Following the transaction, the chief executive officer now owns 612,661 shares of the company's stock, valued at approximately $8,589,507.22. This represents a 16.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders bought 58,829 shares of company stock valued at $757,298 over the last quarter.
About Grail
(
Get Free Report)
GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
See Also
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
